<p>Daré Bioscience（DARE）已举行其第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的_ETF_ AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
<p>Daré Bioscience 最近的财报电话会议描绘了一幅公司在商业和临床管道上取得重大进展的图景，得益于强大的财务管理和战略合作伙伴关系。尽管对不断上升的费用和资本生成的限制存在担忧，但整体情绪是积极的，产品开发和财务健康的进展掩盖了这些挑战。</p>
<h2>DARE to PLAY 西地那非乳膏的商业发布</h2>
<p>Daré Bioscience 即将推出 DARE to PLAY 西地那非乳膏，将对女性性健康产生重大影响。该产品预计将在年底前通过 503B 外包设施上市，此次发布标志着公司的一项重大里程碑，并突显了其解决女性健康未满足需求的承诺。</p>
<h2>强劲的财务状况</h2>
<p>公司报告称财务状况强劲，季度末现金及现金等价物约为 2300 万美元。这得益于 1870 万美元的普通股销售和 730 万美元的补助金支付，展示了有效的财务管理和战略资本配置。</p>
<h2>基于补助金的项目进展</h2>
<p>Daré Bioscience 的战略合作和严格的资本配置在 Ovaprene 和 DARE-HPV 等关键项目的推进中得以体现。这些项目得到了补助金的支持，突显了公司对创新和解决关键健康问题的承诺。</p>
<h2>即将推出的产品</h2>
<p>展望未来，Daré Bioscience 计划在 2026 年第一季度推出 DARE to RESTORE 阴道益生菌产品，并在 2027 年初推出 DARE to RECLAIM 激素疗法。这些发布是公司扩展产品线和增强市场地位战略的一部分。</p>
<h2>管理费用增加</h2>
<p>公司报告称一般和行政费用增加至 250 万美元，较去年同期的 200 万美元有所上升。这一增长归因于专业服务和商业准备费用，反映了公司对未来增长的投资。</p>
<h2>ATM 容量有限</h2>
<p>Daré Bioscience 面临着 “婴儿货架” 限制的挑战，这限制了 ATM 的使用并影响潜在的资本生成。这一限制对公司寻求融资其雄心勃勃的增长计划构成了担忧。</p>
<h2>前瞻性指导</h2>
<p>在财报电话会议中，Daré Bioscience 提供了关于其战略举措和 2025 年第三季度财务表现的详细指导。公司正在追求双路径战略，专注于通过 503B 配方的商业化并寻求 FDA 批准。此外，公司正在推进部分解决方案作为无需处方的品牌消费健康产品。凭借强劲的财务状况和稳健的管道，Daré有良好的基础来实现其战略目标。</p>
<p>总之，Daré Bioscience 的财报电话会议反映出公司正处于显著增长的边缘，推动力来自战略产品发布和强大的财务管理。尽管存在费用增加和资本生成限制等挑战，但整体情绪依然积极，公司在女性健康产品和财务健康方面的进展成为焦点。</p>

DARE

<p>Daré Bioscience 第三季度的财报电话会议强调了其商业和临床管道的显著增长，这得益于强有力的财务管理和战略合作伙伴关系。关键进展包括即将推出的 DARE to PLAY 西地那非乳膏，以及在资助项目如 Ovaprene 和 DARE-HPV 方面的进展。尽管面临如费用增加和有限的 ATM 能力等挑战，公司仍保持积极的前景，计划未来推出新产品，并采取双轨策略以实现商业化和 FDA 批准</p>

<p>Daré Bioscience ((DARE)) has held its Q3 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Daré Bioscience（DARE）已举行其第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的_ETF_ AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
</div><p>Daré Bioscience’s recent earnings call painted a picture of a company making significant strides in its commercial and clinical pipeline, buoyed by robust financial management and strategic partnerships. While there were concerns about rising expenses and limitations in capital generation, the overall sentiment was positive, with the advancements in product development and financial health overshadowing the challenges.</p>
<div class="lb-trans"><p>Daré Bioscience 最近的财报电话会议描绘了一幅公司在商业和临床管道上取得重大进展的图景，得益于强大的财务管理和战略合作伙伴关系。尽管对不断上升的费用和资本生成的限制存在担忧，但整体情绪是积极的，产品开发和财务健康的进展掩盖了这些挑战。</p>
</div><h2>Commercial Launch of DARE to PLAY Sildenafil Cream</h2>
<div class="lb-trans"><h2>DARE to PLAY 西地那非乳膏的商业发布</h2>
</div><p>Daré Bioscience is set to make a significant impact on women’s sexual health with the upcoming launch of DARE to PLAY Sildenafil Cream. Scheduled to be available through a 503B outsourcing facility by the end of the year, this launch marks a major milestone for the company and highlights its commitment to addressing unmet needs in women’s health.</p>
<div class="lb-trans"><p>Daré Bioscience 即将推出 DARE to PLAY 西地那非乳膏，将对女性性健康产生重大影响。该产品预计将在年底前通过 503B 外包设施上市，此次发布标志着公司的一项重大里程碑，并突显了其解决女性健康未满足需求的承诺。</p>
</div><h2>Strong Financial Position</h2>
<div class="lb-trans"><h2>强劲的财务状况</h2>
</div><p>The company reported a strong financial position, ending the quarter with approximately $23 million in cash and cash equivalents. This was bolstered by $18.7 million from sales of common stock and $7.3 million in grant payments, showcasing effective financial management and strategic capital allocation.</p>
<div class="lb-trans"><p>公司报告称财务状况强劲，季度末现金及现金等价物约为 2300 万美元。这得益于 1870 万美元的普通股销售和 730 万美元的补助金支付，展示了有效的财务管理和战略资本配置。</p>
</div><h2>Grant-Funded Programs Advancing</h2>
<div class="lb-trans"><h2>基于补助金的项目进展</h2>
</div><p>Daré Bioscience’s strategic collaborations and disciplined capital allocation are evident in the advancement of key programs like Ovaprene and DARE-HPV. These programs are supported by grants, underscoring the company’s commitment to innovation and addressing critical health issues.</p>
<div class="lb-trans"><p>Daré Bioscience 的战略合作和严格的资本配置在 Ovaprene 和 DARE-HPV 等关键项目的推进中得以体现。这些项目得到了补助金的支持，突显了公司对创新和解决关键健康问题的承诺。</p>
</div><h2>Upcoming Product Launches</h2>
<div class="lb-trans"><h2>即将推出的产品</h2>
</div><p>Looking ahead, Daré Bioscience plans to introduce DARE to RESTORE vaginal probiotic products in the first quarter of 2026 and DARE to RECLAIM hormone therapy in early 2027. These launches are part of the company’s strategy to expand its product offerings and strengthen its market position.</p>
<div class="lb-trans"><p>展望未来，Daré Bioscience 计划在 2026 年第一季度推出 DARE to RESTORE 阴道益生菌产品，并在 2027 年初推出 DARE to RECLAIM 激素疗法。这些发布是公司扩展产品线和增强市场地位战略的一部分。</p>
</div><h2>Increased G&amp;A Expenses</h2>
<div class="lb-trans"><h2>管理费用增加</h2>
</div><p>The company reported an increase in general and administrative expenses to $2.5 million, up from $2 million in the same period last year. This increase is attributed to professional services and commercial readiness expenses, reflecting the company’s investment in future growth.</p>
<div class="lb-trans"><p>公司报告称一般和行政费用增加至 250 万美元，较去年同期的 200 万美元有所上升。这一增长归因于专业服务和商业准备费用，反映了公司对未来增长的投资。</p>
</div><h2>Limited ATM Capacity</h2>
<div class="lb-trans"><h2>ATM 容量有限</h2>
</div><p>Daré Bioscience faces challenges with its ‘baby shelf’ limitations, which restrict the use of the ATM and impact potential capital generation. This limitation is a concern for the company as it seeks to finance its ambitious growth plans.</p>
<div class="lb-trans"><p>Daré Bioscience 面临着 “婴儿货架” 限制的挑战，这限制了 ATM 的使用并影响潜在的资本生成。这一限制对公司寻求融资其雄心勃勃的增长计划构成了担忧。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>During the earnings call, Daré Bioscience provided detailed guidance on its strategic initiatives and financial performance for the third quarter of 2025. The company is pursuing a dual path strategy, focusing on the commercialization of proprietary formulations through 503B compounding and seeking FDA approval. Additionally, the company is advancing select solutions as branded consumer health products without prescription requirements. With a strong financial position and a robust pipeline, Daré is well-positioned to achieve its strategic goals.</p>
<div class="lb-trans"><p>在财报电话会议中，Daré Bioscience 提供了关于其战略举措和 2025 年第三季度财务表现的详细指导。公司正在追求双路径战略，专注于通过 503B 配方的商业化并寻求 FDA 批准。此外，公司正在推进部分解决方案作为无需处方的品牌消费健康产品。凭借强劲的财务状况和稳健的管道，Daré有良好的基础来实现其战略目标。</p>
</div><p>In summary, Daré Bioscience’s earnings call reflected a company on the cusp of significant growth, driven by strategic product launches and strong financial management. While challenges such as increased expenses and capital generation limitations exist, the overall sentiment remains positive, with the company’s advancements in women’s health products and financial health taking center stage.</p>
<div class="lb-trans"><p>总之，Daré Bioscience 的财报电话会议反映出公司正处于显著增长的边缘，推动力来自战略产品发布和强大的财务管理。尽管存在费用增加和资本生成限制等挑战，但整体情绪依然积极，公司在女性健康产品和财务健康方面的进展成为焦点。</p>
</div>

Dare Bioscience 的财报电话会议突显了其增长与挑战